FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 323:1433-1437 November 22, 1990 Number 21 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. We report the results of the Heparin-Aspirin Reperfusion Trial, a collaborative study comparing early intravenous heparin with oral aspirin as adjunctive treatment when recombinant tissue plasminogen activator (rt-PA) is used for coronary thrombolysis during acute myocardial infarction. METHODS. Two hundred five patients were randomly assigned to receive either immediate and then continuous intravenous heparin (starting with a 5000-unit bolus; n = 106) or immediate and then daily oral aspirin (80 mg; n = 99) together with rt-PA (100 mg intravenously over a six-hour period) initiated within six hours of the onset of symptoms. We evaluated the patency of the infarct-related artery by angiography 7 to 24 hours after beginning rt-PA infusion, the frequency of reocclusion of the artery by repeat angiography on day 7, and ischemic or hemorrhagic complications during the hospital stay. RESULTS. At the time of the first angiogram, 82 percent of the infarct-related arteries in the patients assigned to heparin were patent, as compared with only 52 percent in the aspirin group (P less than 0.0001). Of the initially patent vessels, 88 percent remained patent after seven days in the heparin group, as compared with 95 percent in the aspirin group (P not significant). The numbers of hemorrhagic events (18 in the heparin and 15 in the aspirin group) and recurrent ischemic events (8 in the heparin and 2 in the aspirin group) were similar in the two groups. CONCLUSIONS. Coronary patency rates associated with rt-PA are higher with early concomitant systemic heparin treatment than with concomitant low-dose oral aspirin. This observation has important implications for clinical practice and should be considered in the design and interpretation of clinical trials involving coronary thrombolytic therapy.

Source Information

Department of Medicine, George Washington University, Washington, DC 20037.

This article has been cited by other articles:

• Goodman, S. G., Menon, V., Cannon, C. P., Steg, G., Ohman, E. M., Harrington, R. A. (2008). Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 708S-775S [Abstract] [Full Text]  
• Peters, R. J.G., Joyner, C., Bassand, J.-P., Afzal, R., Chrolavicius, S., Mehta, S. R., Oldgren, J., Wallentin, L., Budaj, A., Fox, K. A., Yusuf, S., for the OASIS-6 investigators, (2008). The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur Heart J 29: 324-331 [Abstract] [Full Text]  
• Giraldez, R. R., Nicolau, J. C., Corbalan, R., Gurfinkel, E. P., Juarez, U., Lopez-Sendon, J., Parkhomenko, A., Molhoek, P., Mohanavelu, S., Morrow, D. A., Antman, E. M. (2007). Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis. Eur Heart J 28: 1566-1573 [Abstract] [Full Text]  
• Antman, E. M., Morrow, D. A., McCabe, C. H., Murphy, S. A., Ruda, M., Sadowski, Z., Budaj, A., Lopez-Sendon, J. L., Guneri, S., Jiang, F., White, H. D., Fox, K. A.A., Braunwald, E., the ExTRACT-TIMI 25 Investigators, (2006). Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. NEJM 354: 1477-1488 [Abstract] [Full Text]  
• Eikelboom, J. W., Quinlan, D. J., Mehta, S. R., Turpie, A. G., Menown, I. B., Yusuf, S. (2005). Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials. Circulation 112: 3855-3867 [Abstract] [Full Text]  
• Savitz, S. I., Schlaug, G., Caplan, L., Selim, M. (2005). Arterial Occlusive Lesions Recanalize More Frequently in Women Than in Men After Intravenous Tissue Plasminogen Activator Administration for Acute Stroke. Stroke 36: 1447-1451 [Abstract] [Full Text]  
• The CREATE Trial Group Investigators*, (2005). Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation. JAMA 293: 427-435 [Abstract] [Full Text]  
• Wiggins, B. S., Spinler, S. (2004). Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes. Journal of Pharmacy Practice 17: 347-369 [Abstract]  
• Menon, V., Harrington, R. A., Hochman, J. S., Cannon, C. P., Goodman, S. D., Wilcox, R. G., Schunemann, H. J., Ohman, E. M. (2004). Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 549S-575S [Abstract] [Full Text]  
• Antman, E. M., Van de Werf, F. (2004). Pharmacoinvasive Therapy: The Future of Treatment for ST-Elevation Myocardial Infarction. Circulation 109: 2480-2486 [Full Text]  
• The Task Force on the Management of Acute Myocardi, , Van de Werf, F., Ardissino, D., Betriu, A., Cokkinos, D. V., Falk, E., Fox, K. A.A., Julian, D., Lengyel, M., Neumann, F.-J., Ruzyllo, W., Thygesen, C., Underwood, S. R., Vahanian, A., Verheugt, F. W.A., Wijns, W. (2003). Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 24: 28-66 [Full Text]  
• Baker, W. F. Jr (2002). Thrombolytic Therapy. CLIN APPL THROMB HEMOST 8: 291-314  
• Brouwer, M. A., van den Bergh, P. J.P.C., Aengevaeren, W. R.M., Veen, G., Luijten, H. E., Hertzberger, D. P., van Boven, A. J., Vromans, R. P.J.W., Uijen, G. J.H., Verheugt, F. W.A. (2002). Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 106: 659-665 [Abstract] [Full Text]  
• White, H. D. (2002). Further evidence that antithrombotic therapy is beneficial with streptokinase: improved early ST resolution and late patency with enoxaparin. Eur Heart J 23: 1233-1237  
• Simoons, M.L., Krzeminska-Pakula, M., Alonso, A., Goodman, S.G., Kali, A., Loos, U., Gosset, F., Louer, V., Bigonzi, F. (2002). Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 23: 1282-1290 [Abstract]  
• Coussement, P.K, Bassand, J.-P, Convens, C, Vrolix, M, Boland, J, Grollier, G, Michels, R, Vahanian, A, Vanderheyden, M, Rupprecht, H.-J, Van de Werf, F (2001). A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 22: 1716-1724 [Abstract]  
• Ross, A. M., Molhoek, P., Lundergan, C., Knudtson, M., Draoui, Y., Regalado, L., Le Louer, V., Bigonzi, F., Schwartz, W., de Jong, E., Coyne, K. (2001). Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin: Second Trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 104: 648-652 [Abstract] [Full Text]  
• Hirsh, J., Anand, S. S., Halperin, J. L., Fuster, V. (2001). Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association. Arterioscler. Thromb. Vasc. Bio. 21 : e9-e9 [Full Text]  
• Hirsh, J., Anand, S. S., Halperin, J. L., Fuster, V. (2001). Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association. Circulation 103: 2994-3018 [Full Text]  
• Barbash, G. I., Birnbaum, Y., Bogaerts, K., Hudson, M., Lesaffre, E., Fu, Y., Goodman, S., Houbracken, K., Munsters, K., Granger, C. B., Pieper, K., Califf, R. M., Topol, E. J., Van de Werf, F. (2001). Treatment of Reinfarction After Thrombolytic Therapy for Acute Myocardial Infarction : An Analysis of Outcome and Treatment Choices in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO I) and Assessment of the Safety of a New Thrombolytic (ASSENT 2) Studies. Circulation 103: 954-960 [Abstract] [Full Text]  
• Ohman, E. M., Harrington, R. A., Cannon, C. P., Agnelli, G., Cairns, J. A., Kennedy, J.W. (2001). Intravenous Thrombolysis in Acute Myocardial Infarction. Chest 119 : 253S-277S [Full Text]  
• Goldman, L. E., Eisenberg, M. J. (2000). Identification and Management of Patients with Failed Thrombolysis after Acute Myocardial Infarction. ANN INTERN MED 132: 556-565 [Abstract] [Full Text]  
• Awtry, E. H., Loscalzo, J. (2000). Aspirin. Circulation 101: 1206-1218 [Full Text]  
• Iqbal, O., Messmore, H., Hoppensteadt, D., Fareed, J., Wehrmacher, W. (2000). State-of-the-Art Review : Thrombolytic Drugs in Acute Myocardial Infarction. CLIN APPL THROMB HEMOST 6: 1-13  
• Cannon, C. P. (1999). Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol 34: 1395-1402 [Abstract] [Full Text]  
• Jang, I.-K., Brown, D. F. M., Giugliano, R. P., Anderson, H. V., Losordo, D., Nicolau, J. C., Dutra, O. P., Bazzino, O., Viamonte, V. M., Norbady, R., Liprandi, A. S., Massey, T. J., Dinsmore, R., Schwarz, R. P. Jr, the MINT Investigators, (1999). A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) study. J Am Coll Cardiol 33: 1879-1885 [Abstract] [Full Text]  
• Bednar, M. M., Gross, C. E. (1999). Antiplatelet Therapy in Acute Cerebral Ischemia. Stroke 30: 887-893 [Abstract] [Full Text]  
• Bates, S. M., Weitz, J. I. (1999). Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin. Cardiovasc Res 41: 418-432 [Abstract] [Full Text]  
• Chamuleau, S A J, de Winter, R J, Levi, M, Adams, R, Büller, H R, Prins, M H, Lie, K I, Peters, R J G (1998). Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Heart 80: 35-39 [Abstract] [Full Text]  
• Mungall, D., Baker, B. A., Adelman, M. D. (1998). Activated Partial Thromboplastin Time vs Heparin Concentration. Arch Intern Med 158: 1273-1275 [Full Text]  
• White, R. L (1998). Thrombolytic Therapy in Acute Myocardial Infarction Part II: 1997 Update. Asian Cardiovasc. Thorac. Ann. 6: 03-10 [Abstract] [Full Text]  
• Pickering, W., Brozovic, M., Dancy, M., Cohen, H. (1997). Thrombolysis, With or Without Heparin, During the First Nine Weeks After Acute Myocardiat Infarction. CLIN APPL THROMB HEMOST 3: 183-189 [Abstract]  
• McKenzie, C. R., Abendschein, D. R., Eisenberg, P. R. (1996). Sustained Inhibition of Whole-Blood Clot Procoagulant Activity by Inhibition of Thrombus-Associated Factor Xa. Arterioscler. Thromb. Vasc. Bio. 16: 1285-1291 [Abstract] [Full Text]  
• Collins, R., MacMahon, S., Flather, M., Baigent, C., Remvig, L., Mortensen, S., Appleby, P., Godwin, J., Yusuf, S., Peto, R. (1996). Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 313: 652-659 [Abstract] [Full Text]  
• Schaer, G. L., Spaccavento, L. J., Browne, K. F., Krueger, K. A., Krichbaum, D., Phelan, J. M., Fletcher, W. O., Grines, C. L., Edwards, S., Jolly, M. K., Gibbons, R. J. (1996). Beneficial Effects of RheothRx Injection in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction: Results of a Randomized, Double-Blind, Placebo-Controlled Trial. Circulation 94: 298-307 [Abstract] [Full Text]  
• Yao, S.-K., Akhtar, S., Scott-Burden, T., Ober, J. C., Golino, P., Buja, L. M., Casscells, W., Willerson, J. T. (1995). Endogenous and Exogenous Nitric Oxide Protect Against Intracoronary Thrombosis and Reocclusion After Thrombolysis. Circulation 92: 1005-1010 [Abstract] [Full Text]  
• Simes, R.J., Topol, E. J., Holmes, D. R. Jr, White, H. D., Rutsch, W. R., Vahanian, A., Simoons, M. L., Morris, D., Betriu, A., Califf, R. M., Ross, A. M. (1995). Link Between the Angiographic Substudy and Mortality Outcomes in a Large Randomized Trial of Myocardial Reperfusion : Importance of Early and Complete Infarct Artery Reperfusion. Circulation 91: 1923-1928 [Abstract] [Full Text]  
• Gunnarsson, P. S., Sawyer, W. T., Montague, D., Williams, M. L., Dupuis, R. E., Caiola, S. M. (1995). Appropriate Use of Heparin: Empiric vs Nomogram-Based Dosing. Arch Intern Med 155: 526-532 [Abstract]  
• Leya, F., Fareed, J., Walenga, J. (1995). Acute Myocardial Infarction: Diagnosis and Management. CLIN APPL THROMB HEMOST 1: 160-165 [Abstract]  
• Mruk, J. S., Zoldhelyi, P., Webster, M. W.I., Heras, M., Grill, D. E., Holmes, D. R. Jr, Fuster, V., Chesebro, J. H. (1995). Does Antithrombotic Therapy Influence Residual Thrombus After Thrombolysis of Platelet-Rich Thrombus? : Effects of Recombinant Hirudin, Heparin, or Aspirin. Circulation 93: 792-799 [Abstract] [Full Text]  
• Flaker, G. C., Bartolozzi, J., Davis, V., McCabe, C., Cannon, C. P. (1994). Use of a Standardized Heparin Nomogram to Achieve Therapeutic Anticoagulation After Thrombolytic Therapy in Myocardial Infarction. Arch Intern Med 154: 1492-1496 [Abstract]  
• The GUSTO Investigators, (1993). An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction. NEJM 329: 673-682 [Abstract] [Full Text]  
• Anderson, H. V., Willerson, J. T. (1993). Thrombolysis in Acute Myocardial Infarction. NEJM 329: 703-709 [Full Text]  
• (1992). Adult Advanced Cardiac Life Support. JAMA 268: 2199-2241 [Abstract]  
• Pfeffer, M. A., Moye, L. A., Braunwald, E., Basta, L., Brown, E. J. Jr, Cuddy, T. E., Dagenais, G. R., Flaker, G. C., Geltman, E. M., Gersh, B. J., Goldman, S., Lamas, G. A., Packer, M., Rouleau, J. L., Rutherford, J. D., Steingart, R. M., Wertheimer, J. H. (1991). Selection Bias in the Use of Thrombolytic Therapy in Acute Myocardial Infarction. JAMA 266: 528-532 [Abstract]  
• Popma, J. J., Topol, E. J. (1991). Adjuncts to Thrombolysis for Myocardial Reperfusion. ANN INTERN MED 115: 34-44 [Abstract]  
• Gore, J. M., Dalen, J. E. (1991). Cardiovascular Disease. JAMA 265: 3105-3107 [Abstract]  
• Sherry, S., Marder, V. J. (1991). Streptokinase and Recombinant Tissue Plasminogen Activator (rt-PA) Are Equally Effective in Treating Acute Myocardial Infarction. ANN INTERN MED 114: 417-423 [Abstract]  
• Antman, E. M., Louwerenburg, H. W., Baars, H. F., Wesdorp, J. C.L., Hamer, B., Bassand, J.-P., Bigonzi, F., Pisapia, G., Gibson, C. M., Heidbuchel, H., Braunwald, E., Van de Werf, F., for the ENTIRE-TIMI 23 Investigators, (2002). Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 105: 1642-1649 [Abstract] [Full Text]